SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 4,937 Shares

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 4,937 shares of SI-BONE stock in a transaction that occurred on Wednesday, May 7th. The stock was sold at an average price of $17.00, for a total transaction of $83,929.00. Following the completion of the transaction, the chief financial officer now directly owns 265,356 shares in the company, valued at approximately $4,511,052. This trade represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

SI-BONE Stock Performance

SIBN stock opened at $18.51 on Monday. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $787.21 million, a price-to-earnings ratio of -20.12 and a beta of 0.82. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $19.22. The firm has a 50 day moving average of $14.53 and a two-hundred day moving average of $14.83.

SI-BONE (NASDAQ:SIBN) last posted its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.09. The company had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. As a group, equities analysts anticipate that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

Institutional Trading of SI-BONE

Large investors have recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd bought a new stake in SI-BONE in the first quarter worth approximately $34,000. Virtus Fund Advisers LLC acquired a new stake in shares of SI-BONE in the fourth quarter worth $40,000. Mainstream Capital Management LLC acquired a new stake in shares of SI-BONE in the fourth quarter worth $53,000. GAMMA Investing LLC lifted its stake in shares of SI-BONE by 20,352.6% in the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company’s stock worth $55,000 after buying an additional 3,867 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in shares of SI-BONE in the fourth quarter worth $73,000. 98.11% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on SIBN. Needham & Company LLC reaffirmed a “buy” rating and set a $24.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th. Truist Financial boosted their price objective on shares of SI-BONE from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.